Lumen Bio Reports Positive Phase 2 Results from the RePreve Clinical Trial (LMN-201 for C. difficile Infection)

- Global cure observed in 83.3% of LMN-201 recipients versus 36.4% randomized to placebo - LMN-201 treatment plus standard-of-care antibiotics demonstrated a six-fold reduction in C. difficile infection recurrence compared to standard-of-care antibiotics and placebo (9.1% versus 55.6%) -...

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.